Intracerebral Hemorrhage Treatment Collaboration Between Viz.ai and Nico Announced

Viz.ai (San Francisco, CA) announced a collaboration with Nico Corporation (Indianapolis, IN) for the treatment of patients with intracerebral hemorrhage (ICH). According to Viz.ai, the combination of the companies’ technologies will allow for greater efficiencies and enhance patient care.

Viz.ai’s technology is used to detect suspected disease earlier and receive accurate volume measurements of brain bleeds to assess the severity of cases. Nico’s BrainPath (Nico Corporation, Indianapolis, IN) provides early and safe access to the brain. Its Myriad system allows maximal evacuation of the clot.

With the AI-powered Viz ICH Plus module (Viz.ai, San Francisco, CA), hospital and health systems can automate the process of identifying, labeling, and quantifying the volume of segmentable brain structures on noncontrast CT images. Radiologists, neurologists, and neurosurgeons can incorporate Viz ICH Plus seamlessly into their workflows, detect brain bleeds, and automate the manual process of measurement of brain bleeds.

The company noted that the results of the ENRICH trial (NCT02880878) demonstrated that early minimally invasive parafascicular surgery intervention—or MIPS—using Nico’s BrainPath and Myriad technologies is safe and superior for ICH treatment compared to guideline-based medical management alone, the current standard of care. The ENRICH trial showed improved functional and economic outcomes for ICH. Results from the ENRICH trial were published in The New England Journal of Medicine.

Neurointerventional news coverage produced in conjunction with Endovascular Today.